Biorestorative Therapies (NASDAQ:BRTX) Trading Up 0.4% – What’s Next?

Biorestorative Therapies, Inc. (NASDAQ:BRTX) shares traded up 0.4% during mid-day trading on Thursday . The company traded as high as $1.18 and last traded at $1.1550. 14,932 shares were traded during trading, a decline of 39% from the average session volume of 24,448 shares. The stock had previously closed at $1.15.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Biorestorative Therapies in a research report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

Biorestorative Therapies Price Performance

The stock has a market cap of $10.26 million, a PE ratio of -0.79 and a beta of 0.28. The business has a 50 day moving average price of $1.15 and a two-hundred day moving average price of $1.41.

Biorestorative Therapies (NASDAQ:BRTX) last issued its earnings results on Wednesday, November 12th. The company reported ($0.38) EPS for the quarter, hitting the consensus estimate of ($0.38). Biorestorative Therapies had a negative net margin of 3,308.09% and a negative return on equity of 231.08%. The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.46 million. On average, sell-side analysts forecast that Biorestorative Therapies, Inc. will post -1.43 earnings per share for the current fiscal year.

Institutional Trading of Biorestorative Therapies

A hedge fund recently bought a new stake in Biorestorative Therapies stock. Citadel Advisors LLC bought a new position in Biorestorative Therapies, Inc. (NASDAQ:BRTX) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 106,210 shares of the company’s stock, valued at approximately $152,000. Citadel Advisors LLC owned approximately 1.20% of Biorestorative Therapies at the end of the most recent quarter. 69.38% of the stock is currently owned by institutional investors and hedge funds.

Biorestorative Therapies Company Profile

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.